Shalini Singh | Clinical Pharmacology | Women Researcher Award

Published on by Top Pharmaceutical

Women Researcher Award

Shalini Singh
Global Cosmetic Regulatory Services Pvt Ltd, India

Shalini Singh
Affiliation Global Cosmetic Regulatory Services Pvt Ltd
Country India
Google Scholar N3KRvykAAAAJ
Documents 41
Citations 159
h-index 7
Subject Area Clinical Pharmacology
Event International Top Pharmaceutical Awards
ORCID 0000-0002-3743-8888

Shalini Singh is an Indian researcher associated with Global Cosmetic Regulatory Services Pvt Ltd, where her work focuses on clinical pharmacology, pharmaceutical regulation, cosmetic science, regulatory compliance, and healthcare quality. Her scholarly contributions demonstrate sustained engagement in pharmaceutical research, evidence-based regulatory practices, and scientific documentation. Through peer-reviewed publications and collaborative investigations, she has contributed to improving regulatory understanding and pharmaceutical safety within both academic and industrial environments.[1] Her research profile reflects interdisciplinary expertise spanning clinical pharmacology, pharmaceutical sciences, cosmetic regulation, and healthcare innovation.[2]

Abstract

Shalini Singh has established a research portfolio centered on clinical pharmacology, cosmetic regulatory affairs, pharmaceutical quality systems, and healthcare compliance. Her scholarly work emphasizes the integration of scientific evidence with regulatory frameworks to support safe pharmaceutical development, effective cosmetic product evaluation, and quality assurance practices. Through published research and professional collaborations, she has contributed to advancing regulatory science while promoting responsible innovation across pharmaceutical and cosmetic industries. Her publication record, citation profile, and continued academic engagement indicate consistent participation in multidisciplinary pharmaceutical research.[1][3]

Keywords

Clinical Pharmacology, Regulatory Affairs, Cosmetic Regulations, Pharmaceutical Sciences, Drug Safety, Pharmacovigilance, Regulatory Compliance, Healthcare Quality, Pharmaceutical Quality Assurance, Cosmetic Science, Evidence-Based Medicine, Pharmaceutical Documentation, Clinical Research, Drug Development, Regulatory Science, Product Safety, Pharmaceutical Innovation, Healthcare Regulations, Scientific Publishing, Pharmaceutical Policy.

Introduction

Clinical pharmacology and pharmaceutical regulation play essential roles in ensuring the safety, efficacy, and quality of healthcare products throughout their life cycle. Researchers working in these fields contribute to scientific advancement by strengthening regulatory systems, supporting evidence-based decision-making, and improving public health outcomes. Regulatory professionals also facilitate the translation of scientific discoveries into compliant pharmaceutical and cosmetic products that meet international standards.[2]

Research Profile

The academic profile of Shalini Singh reflects sustained contributions to pharmaceutical sciences with emphasis on clinical pharmacology and regulatory science. Her scholarly metrics include forty-one indexed publications, one hundred fifty-nine citations, and an h-index of seven, indicating continued academic visibility and citation impact within her research community.[1]

Research Contributions

Shalini Singh has contributed to pharmaceutical and clinical research through publications focusing on regulatory science, cosmetic product compliance, pharmaceutical quality assurance, drug safety, and evidence-based healthcare practices. Her research supports the development of scientifically validated regulatory frameworks while encouraging harmonization between pharmaceutical innovation and international compliance standards.[2][3]

Publications

The publication portfolio of Shalini Singh demonstrates continuous scholarly activity within pharmaceutical sciences and clinical pharmacology. Her research output includes peer-reviewed articles addressing regulatory science, pharmaceutical development, healthcare quality, cosmetic regulations, and related multidisciplinary areas. Collectively, these publications have contributed to academic discussions concerning pharmaceutical quality assurance and regulatory compliance.[1]

Research Impact

The measurable research impact of Shalini Singh is reflected through publication productivity, citation performance, and continuing engagement with pharmaceutical and regulatory research communities. Her work contributes to scientific understanding of clinical pharmacology, pharmaceutical quality systems, cosmetic regulation, and healthcare policy. Citation indicators demonstrate that her publications have been referenced by subsequent investigations, supporting ongoing knowledge development within pharmaceutical sciences.[1][2]

Award Suitability

Based on her documented publication record, research activity, citation profile, and professional engagement within clinical pharmacology and pharmaceutical regulation, Shalini Singh demonstrates characteristics commonly associated with recognition under the Women Researcher Award presented at the International Top Pharmaceutical Awards. Her contributions illustrate sustained scholarly participation, interdisciplinary collaboration, and commitment to advancing pharmaceutical sciences through research and regulatory excellence.[1][3]

Conclusion

Shalini Singh has established a professional research profile that combines clinical pharmacology, pharmaceutical regulation, cosmetic compliance, and healthcare quality assurance. Through consistent scholarly publications, interdisciplinary collaboration, and evidence-based regulatory research, she contributes to the advancement of pharmaceutical sciences and responsible healthcare innovation. Her academic achievements, publication metrics, and continuing scientific engagement provide a strong foundation for professional recognition within international pharmaceutical research communities.[1][4]

References

  1. Google Scholar. (n.d.). Shalini Singh – Google Scholar Profile. https://scholar.google.com/citations?user=N3KRvykAAAAJ
  2. Singh, S., Arya, V., Mishra, R. K., & Rajput, S. K. (2026). Clinical Effectiveness of Naturopathic Therapeutic Approaches in the Management of Polycystic Ovary Syndrome: Real-World Evidence. Current Indian Science. Advance online publication. https://doi.org/10.2174/012210299X481816260630115057
  3. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., Mishra, S., & Rana, M. (2025). Mechanistic and Phytopharmacological Insights into Ayurvedic Botanicals for the Management of Polycystic Ovarian Syndrome. Journal of Ayurvedic and Herbal Medicine. https://doi.org/10.4103/JAHM.JAHM_55_25
  4. Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., & Dhanasekaran, M. (2024). Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. Next Research. https://doi.org/10.1016/j.nexres.2024.100004
  5. Balkrishna, A., Rana, M., Mishra, S., Srivastava, D., Bhardwaj, R., Singh, S., Rajput, S. K., Arya, V., & Rigano, D. (2023). Incredible Combination of Lifestyle Modification and Herbal Remedies for Polycystic Ovarian Syndrome Management. Evidence-Based Complementary and Alternative Medicine. 
    https://doi.org/10.1155/2023/3705508

Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Ms. Wai Har Ng | Drug Discovery and Development | Best Researcher Award

Senior Research Associate at National Cancer Centre Singapore | Singapore

Ms. Wai Har Ng is a Senior Research Associate at the National Cancer Centre Singapore with over two decades of experience in cancer biology and translational research. His scientific journey spans genetic engineering, molecular oncology, and personalized therapeutics, with a strong focus on hepatocellular carcinoma, peritoneal carcinomatosis, and colorectal cancer. A dynamic contributor to national research consortiums, Ng WH has authored numerous high-impact publications and excels in molecular, cellular, and in vivo experimental platforms. Known for his collaborative spirit, he plays a pivotal role in mentoring, protocol development, and driving clinical translation in cancer therapy through precision medicine and molecular marker discovery.

Publication Profile 

Scopus

Education

Ms. Wai Har Ng obtained a Master of Science in Genetic Engineering from University Putra Malaysia (2005), where his dissertation focused on gene expression profiling of oil palm root systems using EST and microarray technology. He earned his Bachelor of Science in Biotechnology (2000) from the same university, working on Arabidopsis root transformation. His foundational education was completed at Chong Hwa Independent High School, Kuala Lumpur, from 1990–2000, with certifications including STPM, SPM, and SRP. His early academic training at SRJK (C) Tsun Jin laid the groundwork for a career defined by scientific curiosity, discipline, and innovation in molecular biosciences.

Experience 

Ms. Wai Har Ng currently serves as a Senior Research Associate at the National Cancer Centre Singapore (2017–present), where he spearheads research on molecular therapeutics and biomarker discovery. He previously worked as a Research Officer and Research Associate at the same institute (2004–2017), contributing to groundbreaking oncology studies. Earlier, he served at the Malaysian Agricultural Research & Development Institute (MARDI) from 2003–2004. His academic skillset spans molecular biology, proteomics, imaging, animal studies, and lab management. Proficient in BSL2 safety, grant collaboration, and multidisciplinary research, he plays a key role in mentoring, lab operations, and translational biomedical research.

Awards 

While specific awards were not listed, Ng WH’s achievements are evident through his prolific publication record in high-impact journals, participation in national research consortia like the Singapore Peritoneal Oncology Study (SPOS) and Singapore Gastric Cancer Consortium (SGCC), and recognition as a core contributor to precision oncology research. His co-authorship on influential studies in Scientific Reports, Cell Reports Medicine, and International Journal of Molecular Sciences demonstrates academic recognition and leadership. His technical versatility and mentorship roles further highlight his contribution to national cancer research excellence. If formal awards were earned, these would further bolster his already commendable profile.

Research Focus 

Ng WH focuses on translational cancer research with emphasis on hepatocellular carcinoma, colorectal cancer, peritoneal carcinomatosis, and liposarcoma. His work integrates drug synergy, molecular profiling, biomarker discovery, and machine learning to optimize personalized cancer therapies. He is proficient in CRISPR, ddPCR, organoid modeling, xenografts, and immunofluorescence microscopy. A key area includes developing predictive molecular signatures for chemotherapy response and leveraging advanced imaging to study tumor behavior. With over 13 peer-reviewed publications, Ng WH bridges basic science and clinical application, contributing to a future where cancer treatment is personalized, precise, and highly effective.

Publication Top Notes

Title: Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 5

Title: Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma
Journal: International Journal of Molecular Sciences
Year: 2024
Citations: 4

Conclusion

Ms. Wai Har Ng is a highly competent and experienced researcher whose scientific contributions have advanced the field of cancer biology and therapeutics. Her technical mastery, consistent publication output, and collaborative involvement with national research consortia highlight her as a valuable asset to the research community. With increased visibility through leadership roles in publications and funding acquisition, she would stand out even more prominently. She is a strong and deserving candidate for the Best Researcher Award, given her sustained excellence, innovation, and impact in translational cancer research.

Sebastian Ludwig | Clinical Trials | Best Research Article Award

Published on by Top Pharmaceutical

Sebastian Ludwig | Clinical Trials | Best Research Article Award

Assist. Prof. Dr. Sebastian Ludwig, Universität zu Köln, Germany

Dr. Sebastian Ludwig (b. 1982, Leipzig) is a distinguished gynecologist and urogynecologist, currently serving as Senior Consultant and Head of the Continence and Pelvic Floor Center at the University of Cologne. He earned his medical degree from Ruhr-University Bochum (2009) and completed his habilitation in 2023, focusing on standardization in urogynecological surgery. Dr. Ludwig is a certified clinical trial leader and expert in minimally invasive surgery. Passionate about women’s health, he plays a vital role in medical education. Married with one child, he resides in Cologne.

Publication Profile

Scopus

Education

Assist. Prof. Dr. Sebastian Ludwig 🎓 holds a Doctor of Medicine degree (magna cum laude) and has further distinguished himself by completing his habilitation, earning the venia legendi in Gynecology and Obstetrics. 🏥 His academic journey reflects a deep commitment to medical education, clinical research, and advancing women’s healthcare. With a passion for innovation and evidence-based practice, Dr. Ludwig continues to contribute significantly to his field, shaping the future of gynecological and obstetric medicine. His dedication to both patient care and academic excellence makes him a respected figure in medical education and research. 🔬📚

Experience

Assist. Prof. Dr. Sebastian Ludwig 🏥 has advanced through the medical ranks, starting as an assistant physician and progressing to Oberarzt (senior physician) at the University of Cologne’s Women’s Clinic. His expertise and leadership extend further as the Head of the Continence and Pelvic Floor Center, where he plays a pivotal role in specialized patient care and groundbreaking research. 🔬 His dedication to women’s health, particularly in urogynecology, underscores his commitment to improving treatment outcomes and advancing medical knowledge. Through his clinical and academic contributions, Dr. Ludwig continues to shape the future of gynecological care. 👨‍⚕️📚

Awards

Assist. Prof. Dr. Sebastian Ludwig 🎓 holds multiple prestigious certifications in clinical trials, urogynaecology, gynecological endoscopy, and medical research methodologies. 🏥🔬 These qualifications reflect his dedication to continuous professional development and adherence to the highest standards of research ethics. His expertise in cutting-edge medical techniques ensures optimal patient care and contributes to the advancement of gynecological science. 📚 His commitment to lifelong learning and innovation strengthens his role as a leading specialist in women’s health, making significant contributions to both clinical practice and academic research. 👨‍⚕️💡

Research Focus

Assist. Prof. Dr. Sebastian Ludwig is a dedicated researcher in minimally invasive gynecologic surgery 🏥🔬, with a primary focus on laparoscopic and open abdominal procedures for treating pelvic organ prolapse and related conditions. His work integrates advanced surgical techniques 🏗️, interdisciplinary approaches, and long-term patient outcomes 📊. His studies on uterine ligament replacement and colorectal-gynecological procedures contribute to improving women’s healthcare 👩‍⚕️💙. His research also explores trends in obstetrics 🤰📉, offering insights into evolving birth practices. With publications in top medical journals 📖🏆, Dr. Ludwig plays a crucial role in advancing female pelvic reconstructive surgery 🩺✨.

Publication Top Notes

Comparison of Open Abdominal and Laparoscopic Bilateral Uterosacral Ligament Replacement: A One-Year Follow-Up Study

Early safety and efficiency outcomes of a novel interdisciplinary laparoscopic resection rectopexy combined with sacrocolpopexy for women with obstructive defecation syndrome and pelvic organ prolapse: a single center study

Shifting Trends in Obstetrics: An 18-year Analysis of Low-risk Births at a German University Hospital

Xia Xiao | Pharmacodynamics | Best Researcher Award

Published on by Top Pharmaceutical

Xia Xiao | Pharmacodynamics | Best Researcher Award

Assoc. Prof. Dr. Xia Xiao, Yangzhou University, China

Assoc. Prof. Dr. Xia Xiao is a distinguished researcher in veterinary microbiology at Yangzhou University. He earned his Ph.D. in Veterinary Science from South China Agricultural University (2015) 🎓, specializing in bacteriophage-mediated antibiotic resistance. His research focuses on antimicrobial pharmacokinetics, novel antimicrobial agents, and bacterial resistance mechanisms 🦠💊. A former visiting scholar at UCLA (2018-2019), Dr. Xiao has published extensively in high-impact journals 📚. His work contributes to the rational use of antibiotics and combating multidrug resistance, advancing veterinary and human medicine alike. 🏆🔍

Publication Profile

Scopus

Education

Assoc. Prof. Dr. Xia Xiao is a leading veterinary microbiologist at Yangzhou University. He earned his Ph.D. in Veterinary Science from South China Agricultural University (2015) 🎓, specializing in bacteriophage-mediated antibiotic resistance. As a former visiting scholar at UCLA (2018-2019) 🌍, his research focuses on antimicrobial pharmacokinetics, novel antimicrobial agents, and bacterial resistance mechanisms 🦠💊. Since 2020, he has been an Associate Professor, contributing to advancements in antibiotic utilization and resistance control. His work plays a crucial role in improving both veterinary and human medicine. 📚

Experience

Assoc. Prof. Dr. Xia Xiao is a veterinary microbiologist at Yangzhou University, specializing in antimicrobial resistance 🦠💊. He earned his Ph.D. from South China Agricultural University (2015) 🎓, focusing on bacteriophage-mediated antibiotic resistance. As a Visiting Scholar at UCLA (2018-2019) 🌍, he expanded his research through international collaborations, enhancing his contributions to the global scientific community 🔬🤝. His work explores antibiotic pharmacokinetics, novel antimicrobial agents, and bacterial resistance strategies. Since 2020, he has been an Associate Professor, making impactful strides in veterinary and human medicine. 📚🏆

Focus Areas

Assoc. Prof. Dr. Xia Xiao is a veterinary microbiologist at Yangzhou University, specializing in antimicrobial resistance and antibiotic optimization 💊📊. He earned his Ph.D. from South China Agricultural University (2015) 🎓 and later expanded his research through international collaboration as a Visiting Scholar at UCLA (2018-2019) 🌍. His work focuses on pharmacokinetics-based antibiotic use, novel antimicrobial development, and strategies to combat bacterial resistance 🏥⚕️. His groundbreaking research on bacteriophage-mediated resistance transmission addresses global health challenges, making significant contributions to veterinary and medical microbiology. 📚🏆

Research Focus

Assoc. Prof. Dr. Xia Xiao’s research primarily focuses on antimicrobial resistance (AMR) 🦠💊, pharmacokinetics/pharmacodynamics (PK/PD) modeling 📊🧪, and bacterial resistance mechanisms 🔬🧫. Her work explores the role of resistance genes, such as mcr-1, blaNDM-5, and tet(X4), in multidrug-resistant pathogens, including Klebsiella pneumoniae and Escherichia coli. She investigates novel strategies to combat AMR, including using natural compounds 🌿, repurposed drugs 💡, and PK/PD-based optimization 📉📈. Her research has significant implications for developing effective treatments against drug-resistant infections in both humans and animals 🏥🐾.

Publication Top Notes

DNA Polymerase IV dinB Favors the Adaptive Fitness of mcr-carrying Bacteria Through a Negative Feedback Regulatory Mechanism

Acetylshikonin Derived From Arnebia euchroma (Royle) Johnst Kills Multidrug-Resistant Gram-Positive Pathogens In Vitro and In Vivo

Acetylshikonin reduces the spread of antibiotic resistance via plasmid conjugation

The Food Additive Benzaldehyde Confers a Broad Antibiotic Tolerance by Modulating Bacterial Metabolism and Inhibiting the Formation of Bacterial Flagella

Gramine sensitizes Klebsiella pneumoniae to tigecycline killing

Characterization of a cfr-bearing integrative and conjugative element in Proteus cibarius coharbouring tet(X6) on the chromosome